title: Family History and Relapse in Pediatric Acute Myeloid Leukemia.
abstract: We report the epidemiology and characteristics of acute myeloid leukemia and outcomes of its treatment with the AML-BFM 83 protocol at the Mahak Pediatric Cancer Treatment and Research Center, Tehran, Iran, from 2007 to 2012. A positive family history of cancer or leukemia was associated with the risk of relapse (family history of cancer in relapse: n = 11; 61%, P = 0.136, leukemia: n = 7; 39%; P = 0.016). Treatment-related mortality was 19% and associated with underweight patients (n = 5; 62.5%; P = 0.158). Event-free and overall survivals were 36% (SE = 3.5) and 44% (SE = 3.4), respectively. These data suggest a possible relationship between family history and relapse rate.
authors.affiliation: Mahak's Pediatric Cancer Treatment and Research Center, Army Medical Science University, Tehran, Iran.
authors.forename: Azim
authors.initials: A
authors.lastname: Mehrvar
authors.affiliation: Mahak's Pediatric Cancer Treatment and Research Center, Islamic Azad University of Qom, Qom, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Tashvighi
authors.affiliation: Mahak's Pediatric Cancer Treatment and Research Center, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Faranoush
authors.affiliation: University Children's Hospital Essen, AML-BFM Study Group, Essen, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Reinhardt
authors.affiliation: Mahak's Pediatric Cancer Treatment and Research Center, Tehran, Iran.
authors.forename: Naghmeh
authors.initials: N
authors.lastname: Niktoreh Mofrad
authors.affiliation: Mahak's Pediatric Cancer Treatment and Research Center, Tehran, Iran.
authors.forename: Amir Abbas
authors.initials: AA
authors.lastname: Hedayati Asl
authors.affiliation: Mahak's Pediatric Cancer Treatment and Research Center, Tehran, Iran.
authors.forename: Mardawij
authors.initials: M
authors.lastname: Alebouyeh
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D012008:Recurrence; D015996:Survival Rate
chemical_list: D003561:Cytarabine; D005047:Etoposide; D003630:Daunorubicin
keywords: acute myeloid leukemia; child; recurrence; survival